Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Open accessThe DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.
Abstract
Purpose: This study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for use worldwide in patients with type 2 diabetes and to provide evidence-based support and reference for the selection of clinical treatment. Methods: Three databases (PubMed, Embase, and Cochrane Library) were searched from their respective inception until September 30, 2022. Only randomized controlled trials comparing the efficacy and safety of GLP-1RAs for treating type 2 diabetes (T2D) were included. The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide. Results: 34 RCTs with 10 GLP-1RAs and 12993 patients were included in the Network Meta-Analysis (NMA). According to the NMA, tirzepatide 15 mg, semaglutide 1.0 mg, PEX168-200μg, oral semaglutide 14 and dulaglutide 1.5 mg reduced HbA1c by -2.23%, -1.57%, -1.12%, -1.10%, -1.09% and body weight by -11.33 kg, -5.99 kg, +0.40 kg, -3.95 kg, -1.87 kg, respectively. There was no significant difference in the rate of adverse events for tirzepatide 15 mg, oral-semaglutide 14 mg, and semaglutide 1.0 mg. PEX168-200μg, tirzepatide 15mg, and oral semaglutide 14mg had Surface Under the Cumulative Ranking (SUCRA) values greater than placebo, and only tirzepatide 15mg and oral semaglutide 14mg were significantly different from placebo in the rate of serious adverse events. All GLP-1RA did not lead to increased incidence of hypoglycemia. Albiglutide 30mg and semaglutide 1.0mg significantly differed from placebo in Adverse Event (AE) withdrawal. Finally, the sensitivity analysis and publication bias analysis results indicate that the study results are reliable. Conclusion: This study’s results showed that GLP-1RAs were effective in lowering HbA1c and reducing body weight without increased incidence of hypoglycemic reactions. In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“Evidence suggests (61, 62) that aggressive reduction of multiple risk factors (weight loss or maintenance, smoking cessation, blood pressure control, lipid-lowering, dietary modification, and exercise) reduces the risk of microvascular and macrovascular complications in patients with diabetes.”
BackgroundTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“9 kg) over 72 weeks of treatment, suggesting that tirzepatide 15mg is also a potential weight loss agent (56).”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citationPrevalence and Control of Diabetes in Chinese Adults
Xu, Y. (2013) · JAMA · doi:10.1001/jama.2013.168118 · Cited by 2,703 · cited 2×
“(3) High-risk trials and type of non-randomized controlled trials.”
BackgroundEconomic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013
Wang, L., Gao, P., Zhang, M., Huang, Z., Zhang, D., Deng, Q., Li, Y., Zhao, Z., Qin, X., Jin, D., et al. (2017) · JAMA · doi:10.1001/jama.2017.7596 · Cited by 1,844
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Li, Y., Teng, D., Shi, X., Qin, G., Qin, Y., Quan, H., Shi, B., Sun, H., Ba, J., Chen, B., et al. (2020) · BMJ · doi:10.1136/bmj.m997 · Cited by 1,580 · cited 1×
“(2) Intervention: 10 GLP-1RAs (“exenatide (including exenatide twice daily and once weekly)” or “liraglutide” or “lixisenatide” or “dulaglutide” or “loxenatide” or “PEX168” or “semaglutide (including oral semaglutide)” or “tirzepatide” or “albiglutide”) +/- other oral antidiabetic drugs (OADs) were taken in the treatm…”
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800256 · Cited by 1,475 · cited 1×
“Evidence suggests (61, 62) that aggressive reduction of multiple risk factors (weight loss or maintenance, smoking cessation, blood pressure control, lipid-lowering, dietary modification, and exercise) reduces the risk of microvascular and macrovascular complications in patients with diabetes.”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Huang, Y., Cai, X., Mai, W., Li, M., & Hu, Y. (2016) · BMJ · doi:10.1136/bmj.i5953 · Cited by 1,012
Self-citationZinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Introduction: Standards of Medical Care in Diabetes—2022
American Diabetes Association (2022) · Diabetes Care · doi:10.2337/dc22-sint · Cited by 807
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Sattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555 · cited 1×
“Stata software was used to perform sensitivity analyses for the primary outcome indicator (HbA1c reduction) after excluding 10 high-risk studies (5, 8, 10, 12, 16, 19, 20, 25, 32, 33) according to results 3.”
MethodDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423 · cited 1×
“18kg reduction in weight with 36 weeks of treatment), and its safety profile was consistent with that of GLP-1 receptor agonists as well as GIP and GLP-1 receptor agonists (57).”
ResultWysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
(2022) · PubMed · doi:10.3760/cma.j.cn112138-20211027-00751 · Cited by 258
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Mosenzon, O., Alguwaihes, A., Leon, J. L. A., Bayram, F., Darmon, P., Davis, T. M. E., Dieuzeide, G., Eriksen, K. T., Hong, T., Kaltoft, M. S., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01344-0 · Cited by 247 · cited 1×
“However, in the CAPTURE study (18) (a multinational, crosssectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries), results showed that the prevalence of cardiovascular disease in Chinese patients with T2DM was 33.”
BackgroundAhrén, B., Johnson, S. L., Stewart, M., Cirkel, D. T., Yang, F., Perry, C., & Feinglos, M. N. (2014) · Diabetes Care · doi:10.2337/dc14-0024 · Cited by 228 · cited 2×
“5% of Chinese patients with T2DM and combined ASCVD were treated with GLP-1RAs with cardiovascular benefit, a large gap between clinical practice and guideline recommendations (19, 20).”
BackgroundMethodAli, M. K., Bullard, K. M., Saydah, S., Imperatore, G., & Gregg, E. W. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30027-5 · Cited by 208 · cited 1×
“Stata software was used to perform sensitivity analyses for the primary outcome indicator (HbA1c reduction) after excluding 10 high-risk studies (5, 8, 10, 12, 16, 19, 20, 25, 32, 33) according to results 3.”
MethodFrias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., & Milicevic, Z. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 149
Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Østoft, S. H., Bagger, J. I., Hansen, T., Pedersen, O., Faber, J., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Diabetes Care · doi:10.2337/dc13-3007 · Cited by 136
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127
Home, P. D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., & Carr, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12414 · Cited by 101
Xie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022) · Clinical Epidemiology · doi:10.2147/clep.s391819 · Cited by 93 · cited 1×
“A related weight loss meta-analysis (15) A B”
BackgroundSelf-citationGao, Y., Yoon, K., Chuang, L., Mohan, V., Ning, G., Shah, S., Jang, H. C., Wu, T.-J., Johns, D., Northrup, J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.037 · Cited by 91
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., de Heer, P., Geelhoed-Duijvestijn, P. H., Kharagjitsingh, A. V., Smit, J. W. A., Lamb, H. J., Rensen, P. C. N., & Jazet, I. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0890-5 · Cited by 90
Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis
Avgerinos, I., Michailidis, T., Liakos, A., Karagiannis, T., Matthews, D. R., Tsapas, A., & Bekiari, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13899 · Cited by 88 · cited 1×
“, Sitagliptin, empagliflozin)), and the oral route of administration is strongly associated with an increase in gastrointestinal adverse events (59).”
BackgroundYu Pan, C., Han, P., Liu, X., Yan, S., Feng, P., Zhou, Z., Lv, X., Tian, H., Jin Kui, Y., Su, B., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2541 · Cited by 71 · cited 1×
“Stata software was used to perform sensitivity analyses for the primary outcome indicator (HbA1c reduction) after excluding 10 high-risk studies (5, 8, 10, 12, 16, 19, 20, 25, 32, 33) according to results 3.”
MethodDerosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70
Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., Öhman, P., & on behalf of the DURATION‐NEO‐2 study investigators (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12908 · Cited by 57
KADOWAKI, T., NAMBA, M., YAMAMURA, A., SOWA, H., WOLKA, A. M., & BRODOWS, R. G. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-296 · Cited by 52
Frias, J. P., Wynne, A. G., Matyjaszek‐Matuszek, B., Bartaskova, D., Cox, D. A., Woodward, B., Li, Y. G., Tham, L. S., & Milicevic, Z. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13764 · Cited by 46 · cited 1×
“Stata software was used to perform sensitivity analyses for the primary outcome indicator (HbA1c reduction) after excluding 10 high-risk studies (5, 8, 10, 12, 16, 19, 20, 25, 32, 33) according to results 3.”
MethodPan, Y., Chen, W., & Wang, Y. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.11.008 · Cited by 45
Xia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 40 · cited 1×
“'s (58) efficacy in lowering HbA1c and body weight.”
BackgroundGao, F., Lv, X., Mo, Z., Ma, J., Zhang, Q., Yang, G., Liu, W., Li, Q., Zhou, J., Bao, Y., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14163 · Cited by 37
Chen, X., Lv, X., Yang, G., Lu, D., Piao, C., Zhang, X., Jiang, H., Xie, Y., Yang, J., Li, X., et al. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12397 · Cited by 33
Lu, C., Wu, T.-J., Shih, K., Ni, E., Reed, V. A., Yu, M. B., Sheu, W. H., & Chuang, L. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.02.027 · Cited by 15
Matsuoka, A., Hirota, Y., Takeda, A., Kishi, M., Hashimoto, N., Ohara, T., Higo, S., Yamada, H., Nakamura, T., Hamaguchi, T., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13132 · Cited by 14 · cited 1×
“1RAs, suggesting that sulfonylureas are an essential contributor to hypoglycemia (55).”
Background
Research works printed but not linked: 5
- International Diabetes Federation. IDF Diabetes Atlas. 10th edn. Brussels, Belgium: International Diabetes Federation (2021).
- Chinese Medical Association Diabetes Branch. Chinese guidelines for the prevention and treatment of type 2 diabetes mellitus (2020 edition). Int J Endocrinol Metab (2021) 41(05): 482– 548. doi: 10.19538/j.nk2021080106 · doi:10.19538/j.nk2021080106
- Jing G. Research progress of glucagon-like peptide-1 receptor agonists in cardiovascular complications of type 2 diabetes mellitus. Modern Diagnosis Ther (2020) 31(19): 3041– 3042+3190.
- Yanlan L Aiwen H Guanxu C Chen T Zhao L Liao X. Cardiovascular benefit of SGLT-2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes: a systematic review and reticulated Meta-analysis. J Pharm Pract (2022) 40(04): 354–8.
- Chang X Jianzhong Z. Recent research progress on the evidence and mechanism of cardiovascular benefit of SGLT2 inhibitors in type 2 diabetes mellitus population. Modern Med Health (2021) 37(15): 2599–604.
Cited by
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.23332 · Cited by 172
Aldhaleei, W. A., Abegaz, T. M., & Bhagavathula, A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17020199 · Cited by 80
Bao, Y., Hu, Y., Shi, M., & Zhao, Z. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16107 · Cited by 50
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
Liu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1397029 · Cited by 37
Breit, S., & Hubl, D. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107415 · Cited by 29
Metadata
- Authors
- Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J.
- Affiliations
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Corresponding author
- Chen, Jisheng
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-08-28
- Volume
- 14
- Pages
- 1244432-1244432
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC10493284
- OpenAlex
- W4386220010
- Cited by
- 47
- References
- 63
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 15 · 2023: 1
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, metformin add-on therapy, tirzepatide, semaglutide, dulaglutide, exenatide, liraglutide, lixisenatide, albiglutide, HbA1c, body weight, adverse events, treatment efficacy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Body Weight, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Metformin, Peptides, Polyethylene Glycols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.